Science & academia

Man and woman embracing

Prostate cancer surgery breakthrough offers hope for erectile function

By / / Good news links

A new form of prostate cancer surgery nearly doubles the chances of men retaining erectile function, according to a new trial conducted by University College London. Known as NeuroSafe, the procedure checks tissue removed during the operation. If the tumor appears to have been removed, the nerve-containing outer layer of the prostate is left intact. The trial assessed 344 men with prostate cancer and no history of erectile dysfunction. 56% of men who had standard surgery reported severe erectile dysfunction, compared with 38% who had NeuroSafe surgery.

Satellite from above with Earth below|nasa unsplash

First Earth Fire Alliance satellite for detecting wildfires is now in orbit

By / / Good news links

The FireSat constellation, which will consist of more than 50 satellites when it goes live, is the first of its kind that’s built to detect and track fires. It’s an initiative launched by nonprofit Earth Fire Alliance, which includes Google and Muon Space as partners, among others. According to Google, current satellite systems rely on low-resolution imagery and cover a particular area only once every 12 hours to spot large wildfires spanning a couple of acres. FireSat will be able to detect wildfires as small as the size of a classroom and deliver high-resolution visual updates every 20 minutes.

Battery illustration

Chinese researchers develop new battery recycling process that recovers 99.99% of lithium

By / / Good news links

The groundbreaking method, developed by researchers from Central South University, Guizhou Normal University, and the National Engineering Research Center of Advanced Energy Storage Materials, employs a unique ‘battery effect’ mechanism. The process achieves remarkable recovery rates: 99.99% of lithium, 96.8% of nickel, 92.35% of cobalt, and 90.59% of manganese, all within just 15 minutes. Unlike traditional methods, this approach avoids harsh chemicals and minimizes environmental harm, generating effluents suitable for use as fertilizer.

Good news for public health

Annual jab for HIV protection passes trial hurdle

By / / Good news links

An annual injection designed by California’s Gilead Sciences to guard against HIV has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the virus from replicating inside cells. For the trial, 40 people without HIV were injected into the muscle with lenacapavir, with no major side effects or safety concerns. And after 56 weeks, the medicine was still detectable in their bodies. If future trials go well, it could become the longest-acting form of HIV prevention available.

Human eye up close

Stem cell therapy trial reverses “irreversible” damage to cornea

By / / Good news links

A new study conducted by scientists at Massachusetts Eye and Ear investigated a new treatment that removes stem cells from a patient’s uninjured eye, growing their population in the lab for a few weeks, then surgically transplanting them into the injured eye. The phase 1/2 trial recruited 14 patients to undergo the procedure. By the first checkup at three months, the corneas of seven (50%) of the participants had been completely restored. By the 12-month mark, that number had increased to 11 (79%) patients.

Illustration of the concept of nuclear fusion

France runs fusion reactor for record 22 minutes

By / / Good news links

Achieving the dream of commercial fusion power is the Holy Grail of engineering and has been for 80 years. With a single gram of hydrogen isotopes yielding the energy equivalent of 11 tonnes of coal, a practical fusion reactor would hold the promise of unlimited, clean energy for humanity until the end of time. France has upped the ante in the quest for fusion power by maintaining a plasma reaction for over 22 minutes – 25% longer than the previous record set by China in January 2025.

Two people holding hands

U.S. approves “milestone” Parkinson’s treatment for 2025 release

By / / Good news links

The treatment, which will be sold under the name Onapgo, is essentially a subcutaneous – under the skin – device that allows for continuous infusion of the dopamine agonist apomorphine hydrochloride to reduce ‘off’ episodes. These episodes are periods during the day and night when lepodova medication wears off and adverse motor-function symptoms become amplified. In trial, Onapgo significantly reduced these daily off episodes by an average of 2.47 hours, compared to the placebo treatment.

Holding pills

U.S. FDA approves non-addictive alternative to opioids

By / / Good news links

The U.S. Food and Drug Administration has signed off on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose. Crucially, suzetrigine creates no euphoria or high like opioids sometimes can, so doctors believe there’s no potential for it to create addiction or dependence in people who use it.

Illustration of the concept of nuclear fusion

China sets new fusion endurance record of over a thousand seconds

By / / Good news links

Fusion power is widely thought of as the holy grail of renewable, climate-friendly energy. Now, we are one step closer to realizing practical fusion power for the masses. The Experimental Advanced Superconducting Tokamak reactor in China’s Anhui Province has set a new record with a 1,066-second sustained fusion reaction. The new record builds on the previous record of 403 seconds set by EAST in 2023. The increase was made possible by a number of upgrades to the experimental system that have doubled the power output while keeping the reaction stable.

Woman with pink breast cancer ribbon

New therapy trial from Australian researchers nearly doubles breast cancer cure rates

By / / Good news links

A phase 3 clinical trial from Melbourne’s Peter MacCallum Cancer Center has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved the cure rate for patients with the most common kind of breast cancer. In the present phase 3 trial, 510 patients were randomized to receive chemotherapy with either intravenous nivolumab or placebo. In patients treated with nivolumab plus chemotherapy, rates were statistically significant, nearly double those who received placebo plus chemo: 24.5% versus 13.8%, respectively.